Tags

Type your tag names separated by a space and hit enter

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.

Abstract

Introduction: Huntington's disease (HD)-associated chorea and tardive dyskinesia (TD) are hyperkinetic movement disorders that can have deleterious effects on patients' quality of life (QoL). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of HD-associated chorea and TD. It is structurally similar to tetrabenazine, an FDA-approved compound for treatment of chorea that is widely used off-label for treatment of TD, but has deuterium modifications that improve its pharmacokinetic profile. Areas covered: Herein, the authors cover the key clinical trials with deutetrabenazine in patients with HD-associated chorea (First-HD and ARC-HD) and in patients with TD (ARM-TD, AIM-TD, and RIM-TD). Expert opinion: Deutetrabenazine demonstrates consistent efficacy across patient types regardless of underlying psychiatric illness, or through use of dopamine-receptor antagonists (DRAs), which are the primary cause of TD. The safety profile of deutetrabenazine in clinical trials is similar to that of placebo. Long-term extension studies in both HD-associated chorea and TD show consistent efficacy and safety. Deutetrabenazine will likely be an integral part of the treatment strategy for HD-associated chorea and TD. Meanwhile, its potential to treat other hyperkinetic movement disorders is still under investigation.

Authors+Show Affiliations

Department of Neurology, Vanderbilt University , Nashville , Tennessee , USA.Teva Pharmaceuticals , Frazer , Pennsylvania , USA.Teva Pharmaceuticals , Frazer , Pennsylvania , USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31613641

Citation

Claassen, Daniel O., et al. "Deutetrabenazine for Tardive Dyskinesia and Chorea Associated With Huntington's Disease: a Review of Clinical Trial Data." Expert Opinion On Pharmacotherapy, 2019, pp. 1-13.
Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Expert Opin Pharmacother. 2019.
Claassen, D. O., Philbin, M., & Carroll, B. (2019). Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Expert Opinion On Pharmacotherapy, pp. 1-13. doi:10.1080/14656566.2019.1674281.
Claassen DO, Philbin M, Carroll B. Deutetrabenazine for Tardive Dyskinesia and Chorea Associated With Huntington's Disease: a Review of Clinical Trial Data. Expert Opin Pharmacother. 2019 Oct 15;1-13. PubMed PMID: 31613641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. AU - Claassen,Daniel O, AU - Philbin,Michael, AU - Carroll,Benjamin, Y1 - 2019/10/15/ PY - 2019/10/16/entrez PY - 2019/10/16/pubmed PY - 2019/10/16/medline KW - Antipsychotics KW - Huntington’s disease KW - VMAT2 inhibitor KW - deutetrabenazine KW - movement disorders KW - tardive dyskinesia KW - tetrabenazine KW - valbenazine SP - 1 EP - 13 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother N2 - Introduction: Huntington's disease (HD)-associated chorea and tardive dyskinesia (TD) are hyperkinetic movement disorders that can have deleterious effects on patients' quality of life (QoL). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of HD-associated chorea and TD. It is structurally similar to tetrabenazine, an FDA-approved compound for treatment of chorea that is widely used off-label for treatment of TD, but has deuterium modifications that improve its pharmacokinetic profile. Areas covered: Herein, the authors cover the key clinical trials with deutetrabenazine in patients with HD-associated chorea (First-HD and ARC-HD) and in patients with TD (ARM-TD, AIM-TD, and RIM-TD). Expert opinion: Deutetrabenazine demonstrates consistent efficacy across patient types regardless of underlying psychiatric illness, or through use of dopamine-receptor antagonists (DRAs), which are the primary cause of TD. The safety profile of deutetrabenazine in clinical trials is similar to that of placebo. Long-term extension studies in both HD-associated chorea and TD show consistent efficacy and safety. Deutetrabenazine will likely be an integral part of the treatment strategy for HD-associated chorea and TD. Meanwhile, its potential to treat other hyperkinetic movement disorders is still under investigation. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/31613641/Deutetrabenazine_for_tardive_dyskinesia_and_chorea_associated_with_Huntington's_disease:_a_review_of_clinical_trial_data L2 - http://www.tandfonline.com/doi/full/10.1080/14656566.2019.1674281 DB - PRIME DP - Unbound Medicine ER -